United Therapeutics

Last updated
United Therapeutics Corporation
Company type Public
Industry Biotechnology
Founded1996;28 years ago (1996)
Headquarters
Silver Spring, Maryland and Research Triangle Park, North Carolina
,
United States
RevenueIncrease2.svg$2.33 Billion (2023) [1]
Number of employees
1,168
Website unither.com

United Therapeutics Corporation is an American publicly traded biotechnology company [2] and public benefit corporation [3] listed on the NASDAQ under the symbol UTHR. [4] [5] It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire. [6]

Contents

History

United Therapeutics was founded in 1996 by Martine Rothblatt, [7] [8] an American lawyer, author, and entrepreneur, who created Sirius XM. [9] In 1994, Rothblatt's young daughter was diagnosed with a fatal orphan disease, pulmonary arterial hypertension (PAH). [10] [8] Rothblatt sold her telecom stock and started the PPH Cure Foundation to fund PAH research. [2] [8]

In 2002, the U.S. Food and Drug Administration (FDA) approved United Therapeutics' drug Remodulin, [11] a prostacyclin vasodilator used to treat PAH. Remodulin provided PAH patients with an alternative to GlaxoSmithKline's Flolan. [10] By 2003, Remodulin annual sales had reached $50 million. [8] By 2010, annual sales were $300 million and United Therapeutics' share price had increased 800 percent from the 1999 initial public offering price. [8]

In 2011, United Therapeutics acquired Revivicor, a company focused on developing genetic biotechnology platforms to provide alternative tissue sources for treatment. [12] With the acquisition of Revivicor, United Therapeutics began the xenokidney program to find alternative sources of organs for patients awaiting a kidney transplant. Xenotransplantation is a potential solution as it possibly could provide a limitless supply of organs.

In 2018, the company acquired SteadyMed, a medical device company developing injectable therapeutic drugs for pulmonary hypertension. [13] Other acquisitions include SynQuest in 1999 and Cooke Pharma in 2000. [14] United Therapeutics has entered numerous licensing agreements and collaborations with companies such as Eli Lilly and Company, DEKA Research & Development, MannKind Corporation, [15] and the National Cancer Institute.

On January 7, 2022, a porcine heart provided by United Therapeutics' Revivicor subsidiary in conjunction with the University of Maryland Medical Center was used in the first pig-to-human transplant operation. [16] The recipient subsequently died on March 8, 2022. [17]

In October 2023, United Therapeutics purchased bioengineering company IVIVA Medical, Inc. for $50 million plus royalties. Sixteen IVIVA employees transferred to United Therapeutics. [18]

In December 2023, United Therapeutics Corporation completed the acquisition of Miromatrix Medical Inc., a biotechnology company that specializes in the development of bioengineered organs composed of human cells. [19]

Medicines

United Therapeutics products are sold in the U.S. and Canada, and its products are available in Central and South America, Europe, the Middle East, and Asia through various distribution partners. [20] In the U.S., the company has received multiple approvals from the Food and Drug Administration. [21] These cover various strengths and routes of administration for Orenitram, Remodulin, Tyvaso, and Tyvaso DPI, each indicated for the treatment of pulmonary arterial hypertension. Tyvaso and Tyvaso DPI are also indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics also markets Adcirca (tadalafil) for the treatment of pulmonary arterial hypertension under a licensing agreement with Eli Lilly and Company. [22]

In February 2020, the U.S. Food and Drug Administration granted clearance for the Unity Subcutaneous Delivery System for Remodulin Injection, also known as the Remunity pump, allowing the system to be used with drug cassettes that have been prefilled by specialty pharmacies. [23] The Remunity system allows for constant, subcutaneous (under-the-skin) delivery of Remodulin. The Remunity system is indicated for the treatment of pulmonary arterial hypertension in patients older than 22.[ citation needed ]

In March 2015, the U.S. FDA approved United Therapeutics' Biologics License Application (BLA) for Unituxin. [24] Unituxin is a monoclonal antibody used as a second-line treatment for children with high-risk neuroblastoma, a rare form of cancer.

In May 2022, the U.S. FDA approved United Therapeutics' New Drug Application (NDA) for Tyvaso DPI. [25] Tyvaso DPI is a dry powder inhaler containing treprostinil and is indicated for both PAH and PH-ILD.

Research

United Therapeutics is advancing a pipeline of research and development projects that includes new indications, formulations, and delivery devices for its existing products. The company's R&D pipeline includes five registration phase studies, primarily in rare lung diseases, and seven preclinical product leads, primarily in organ manufacturing.

In February 2020, United Therapeutics reported that it had successfully completed the INCREASE study of Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and that the study met its primary endpoint of demonstrating improvement in six-minute walk distance (6MWD). [26] The company submitted the INCREASE study results to the U.S. Food and Drug Administration in support of an efficacy supplement to the Tyvaso New Drug Application and received approval on March 31, 2021. [27]

Ongoing clinical trials of new medicines include ADVANCE OUTCOMES (Phase 3) for ralinepag in pulmonary arterial hypertension; a registration study of the Centralized Lung Evaluation System; [28] and TETON 1 and TETON 2 for idiopathic pulmonary fibrosis (IPF). [29]

United Therapeutics is developing a unique type of biopharmaceutical medicinal product known as a manufactured organ. This type of biologic would be transplanted into the patient as a substitute for a failing organ. The company has regenerative medicine products such as these being developed via xenotransplantation, allogenic recellularization, and autologous bioprinting technologies. [30]

In 2021, researchers at New York University used a ThymoKidney xenokidney in the first transplant of a genetically engineered, nonhuman kidney into a brain-dead human body, observing kidney function over 54 hours. [31] Researchers at The University of Alabama at Birmingham used a UKidney xenokidney in a transplant into a brain-dead recipient, observing kidney function over 77 hours. [32]

In 2021, engineers from the company's Unither Bioelectronics subsidiary conducted the first flight of human lungs for transplant from Toronto Western Hospital to Toronto General Hospital. [33] The lungs were successfully transplanted into Alain Hodak, an engineer from Ottawa, Canada. [34]

In 2022, the UHeart xenoheart was used in the first pig heart to living human transplant. [35] The transplanted pig heart had ten genetic modifications to the pig genome. [36]

In 2022, Martine Rothblatt debuted a 3D printed lung scaffold that was what she called one of the "most complex 3D printed objects ever printed." [37] The printed lung scaffold contained 44 trillion voxels that laid out 4,000 kilometers of pulmonary capillaries and 200 million pulmonary alveoli.

Operations

United Therapeutics owns a 415,000-square-foot combination laboratory and office building complex in Silver Spring, Maryland. The facility serves as the company's co-headquarters and is used for commercial manufacturing of active pharmaceutical ingredients and finished dosage form products. United Therapeutics also owns a 380,000-square-foot combination manufacturing plant and office building in Research Triangle Park, North Carolina. The facility serves as the company's co-headquarters and is occupied by clinical research and development, commercialization, logistics, manufacturing, and packaging personnel. Adjacent to its Research Triangle Park complex, United Therapeutics owns a 132-acre site containing approximately 330,000 square feet of building space that is used for research, development and manufacturing related to the company's lung regeneration program. This site is available for future expansion. [38]

United Therapeutics subsidiaries include Lung Biotechnology PBC; Lung Bioengineering Inc.; Miromatrix Medical; United Therapeutics Europe, Ltd.; Unither Biotech Inc., Canada; Unither Pharma, LLC; Unither Telmed, Ltd.; Unither Bioélectronique, Quebec; IVIVA Medical; and Revivicor, Inc. [39] As of December 2023, United Therapeutics had a global workforce of 1,168. [40] On June 1, 2024, United Therapeutics' market capitalization was $12.3 billion. [41]

Lung Biotechnology PBC

United Therapeutics' subsidiary Lung Biotechnology PBC was the first public benefit corporation subsidiary of a publicly traded biopharmaceutical company. Utilizing perfusion, Lung Biotechnology pursued innovative technology that could preserve lungs for transplant by stabilizing lungs that would otherwise be discarded. The objective was to address the acute shortage of transplantable lungs for patients with end-stage lung disease, including PAH.

Corporate social responsibility

In 2020, United Therapeutics established a minimum "living wage" of approximately $75,000 per year for employees, inclusive of incentive pay. Fulltime employees are shareholders of the company through United Therapeutics' long-term incentive programs. United Therapeutics has been recognized as one of the Top 10 Corporate Citizens in the field of U.S. drug manufacturing, along with companies such as Amgen, Johnson & Johnson, and Bristol-Myers Squibb. [42] United Therapeutics was named on Fortune's Best Workplaces in Health Care & Biopharma 2021 [43] (third consecutive year); The Washington Post's Top Workplaces for 2020 [44] (sixth consecutive year); Fortune's Best Small & Medium Workplaces 2020 [45] (third consecutive year); and Fortune's Best Workplaces for Millennials™ 2020. [46] In 2019, United Therapeutics received Women in Technology's Corporate Board Award and was named on Triangle Business Journal's "Best Places to Work List" for the sixth consecutive year. [47] The company was also named to Newsweek's America's Most Responsible Companies list in 2022 [48] and 2023. [49]

United Therapeutics facilities include one Platinum and two Gold LEED certified buildings, as rated by the U.S. Green Building Council, and four net zero buildings located across three states. Innovative, energy-efficient building design, multiple solar arrays, purchase of renewable energy credits (RECs) and carbon offsets, and other green energy technologies have enabled United Therapeutics to achieve a sustainable urban campus. At the time of its construction, United Therapeutics' site net-zero "Unisphere," a 135,000 square foot high-rise office building in Silver Spring, Maryland, was the largest urban office building to be energy positive. Using extensive solar arrays, heat mediating wells, and other leading-edge design technologies, Unisphere generates more energy on site than it consumes.

United Therapeutics has implemented corporate governance best practices ahead of industry peers and the Russell 3000. These include adopting majority voting and proxy access policies, initiating a Board declassification process, and imposing a tighter limit on director outside board membership. The Board of Directors engages with company shareholders multiple times each year to discuss governance and operations priorities. In 2020, 2021, and 2022, United Therapeutics published a comprehensive Corporate Social Responsibility report. [50]

In 2021, United Therapeutics shareholders approved the conversion of the company into a public benefit corporation (PBC). [3] As a PBC, United Therapeutics, while creating value for shareholders, must also consider the best interests of those materially affected by the company's conduct and the specific public benefit that it chooses to adopt in its charter. PBCs like United Therapeutics are intended to produce public benefits and to operate in a responsible and sustainable manner. United Therapeutics public benefit purpose is "to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs." [51]

Leadership

Martine Aliana Rothblatt, founder and chairperson [52] of the board of United Therapeutics, graduated from University of California, Los Angeles, with J.D. and M.B.A. degrees in 1981. In June 2001, she earned a Ph.D. in medical ethics at the Barts and The London School of Medicine and Dentistry, Queen Mary University of London. Rothblatt worked in Washington, D.C., first in the field of communications satellite law, and eventually in life sciences projects like the Human Genome Project. She also served as the CEO of GeoStar and the creator of SiriusXM Satellite Radio.[8] [7] Michael Benkowitz serves as president and chief operating officer; James Edgemond is chief financial officer and treasurer; Paul Mahon is general counsel. She is also a trans woman.

Related Research Articles

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

<span class="mw-page-title-main">Tadalafil</span> Medication used to treat erectile dysfunction

Tadalafil, sold under the brand name Cialis among others, is a medication used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It is taken by mouth. Onset is typically within half an hour and the duration is up to 36 hours.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Pulmonary hypertension</span> Increased blood pressure in lung arteries

Pulmonary hypertension is a condition of increased blood pressure in the arteries of the lungs. Symptoms include shortness of breath, fainting, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual. According to the definition at the 6th World Symposium of Pulmonary Hypertension in 2018, a patient is deemed to have pulmonary hypertension if the pulmonary mean arterial pressure is greater than 20mmHg at rest, revised down from a purely arbitrary 25mmHg, and pulmonary vascular resistance (PVR) greater than 3 Wood units.

Icos Corporation was an American biotechnology company and the largest biotechnology company in the U.S. state of Washington, before it was sold to Eli Lilly and Company in 2007. It was founded in 1989 by David Blech, Isaac Blech, Robert Nowinski, and George Rathmann, a pioneer in the industry and chief executive officer (CEO) and co-founder of Amgen. Icos focused on the development of drugs to treat inflammatory disorders. During its 17-year history, the company conducted clinical trials of twelve drugs, three of which reached the last phase of clinical trials. Icos also manufactured antibodies for other biotechnology companies.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

<span class="mw-page-title-main">Sitaxentan</span> Chemical compound

Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity.

<span class="mw-page-title-main">Bosentan</span> Medication

Bosentan, sold under the brand name Tracleer among others, is a dual endothelin receptor antagonist medication used in the treatment of pulmonary artery hypertension (PAH).

<span class="mw-page-title-main">Iloprost</span> Pharmaceutical drug

Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues. Iloprost is a prostacyclin mimetic.

<span class="mw-page-title-main">Lung transplantation</span> Surgical procedure in which a patients diseased lungs are partially or totally replaced

Lung transplantation, or pulmonary transplantation, is a surgical procedure in which one or both lungs are replaced by lungs from a donor. Donor lungs can be retrieved from a living or deceased donor. A living donor can only donate one lung lobe. With some lung diseases, a recipient may only need to receive a single lung. With other lung diseases such as cystic fibrosis, it is imperative that a recipient receive two lungs. While lung transplants carry certain associated risks, they can also extend life expectancy and enhance the quality of life for those with end stage pulmonary disease.

<span class="mw-page-title-main">Martine Rothblatt</span> American lawyer, writer and businessperson

Martine Aliana Rothblatt is an American lawyer, author, entrepreneur, and a transgender woman. Rothblatt graduated from University of California, Los Angeles with J.D. and M.B.A. degrees in 1981, then began to work in Washington, D.C., first in the field of communications satellite law, then in bioethics and biomedicine. She is also influential in the field of aviation, particularly electric aviation, as well as with sustainable building.

<span class="mw-page-title-main">Dasatinib</span> Chemical compound

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.

<span class="mw-page-title-main">Ambrisentan</span> Chemical compound

Ambrisentan, sold under the brand name Letairis among others, is a drug used for the treatment of pulmonary hypertension. It is an endothelin receptor antagonist.

Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company's most advanced investigational clinical programs are ralinepag in testing for pulmonary arterial hypertension (PAH), etrasimod in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn's disease. In 2016, the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials. In December 2021, Pfizer announced that it had agreed to acquire Arena for $6.7 billion in cash. In March 2022, it was announced the acquisition by Pfizer had been concluded.

<span class="mw-page-title-main">Riociguat</span> Chemical compound

Riociguat, sold under the brand name Adempas, is a medication by Bayer that is a stimulator of soluble guanylate cyclase (sGC). It is used to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of the class of sGC stimulators. The drug has a half-life of 12 hours and will decrease dyspnea associated with pulmonary arterial hypertension.

<span class="mw-page-title-main">Tofacitinib</span> Medication

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis, and ulcerative colitis. It is a janus kinase (JAK) inhibitor, discovered and developed by the National Institutes of Health and Pfizer.

<span class="mw-page-title-main">Actelion</span> Swiss biopharmaceutical company

Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland.

<span class="mw-page-title-main">Macitentan</span> Chemical compound

Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist (ERA) developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). The other two ERAs marketed as of 2014 are bosentan and ambrisentan. Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype. The drug received approval from the U.S. Food and Drug Administration (FDA) on 13 October 2013.

<span class="mw-page-title-main">Selexipag</span> Chemical compound

Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679, are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. It is taken by mouth or administered intravenously.

Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. It is an activin signaling inhibitor, based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). It is given by subcutaneous injection.

References

  1. ↑ "U.S. Securities and Exchange Commission".
  2. 1 2 "United Therapeutics (UTHR)". Forbes.
  3. 1 2 "United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval". PRNewswire.
  4. ↑ "United Therapeutics Corporation (UTHR) stock price, news, quote & history – Yahoo Finance". uk.finance.yahoo.com.
  5. ↑ "Commit To Buy United Therapeutics At $105, Earn 9% Annualized Using Options". Forbes. September 25, 2014.
  6. ↑ United Therapeutics Corp. "Locations." Accessed October 4, 2020.
  7. ↑ Piore, Adam (July 30, 2021). "Pharma CEO Faces Personal Fight for a New Breed of Organ Donors". Bloomberg News . Retrieved 8 August 2021.
  8. 1 2 3 4 5 Herper, Matthew (April 22, 2010). "From Satellites To Pharmaceuticals". Forbes. Retrieved September 8, 2014.
  9. ↑ Tucker, Neely (December 12, 2014). "Martine Rothblatt: She founded SiriusXM, a religion and a biotech. For starters". Washington Post. Retrieved September 25, 2020.
  10. 1 2 Moukheiber, Zina (July 1, 2002). "Jeni's Oil". Forbes. Retrieved November 19, 2015.
  11. ↑ "Drug Approval Package: Remodulin (Treprostinil Sodium) Injection". FDA. 21 May 2002. Retrieved November 19, 2015.
  12. ↑ "United Therapeutics Corp Biotechnology: Why We Like The Stock". NASDAQ. April 22, 2013. Retrieved September 28, 2020.
  13. ↑ Gilgore, Sara (2021-03-21). "Washington Business Journal". www.bizjournals.com. Retrieved 2022-01-26.
  14. ↑ "United Therapeutics buying Cooke Pharma - Pharmaceutical industry news". www.thepharmaletter.com. Retrieved 2022-01-25.
  15. ↑ "Mannkind Investors". September 4, 2018. Retrieved March 14, 2023.
  16. ↑ "First Pig to Human Heart". Nature Biotechnology. Retrieved March 15, 2023.
  17. ↑ "Man given genetically modified pig heart dies". BBC News. 2022-03-09. Retrieved 2023-08-18.
  18. ↑ "United Therapeutics Corporation acquired IVIVA Medical, Inc. for $50 million". Marketscreener. Archived from the original on 2024-03-25. Retrieved 2024-03-25.
  19. ↑ "United Therapeutics to Acquire Miromatrix Medical". Businesswire. Archived from the original on 2023-11-04. Retrieved 2024-03-25.
  20. ↑ "United Therapeutic Corporation Form 10-K". U.S. Securities and Exchange Commission. February 24, 2022.
  21. ↑ "Approved Drug Products with Therapeutic Equivalence Evaluations". U.S. Food and Drug Administration. October 9, 2020. Retrieved October 9, 2020.
  22. ↑ "United Therapeutics reworks deal ahead of a key patent's expiration". www.bizjournals.com. Retrieved 2022-02-14.
  23. ↑ "United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin". BioSpace. February 24, 2020. Retrieved September 20, 2020.
  24. ↑ "FDA Approves First Therapy for High-Risk Neuroblastoma". National Cancer Institute. March 27, 2015. Retrieved September 30, 2020.
  25. ↑ "FDA Approves Inhaled Treprostinil for PAH and PH-ILD". U.S. Pharmacist. May 24, 2022. Retrieved March 17, 2023.
  26. ↑ "United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints". BioSpace. February 24, 2020. Retrieved September 21, 2020.
  27. ↑ "United Therapeutics Announces FDA Approval and Launch of Tyvaso". PRNewswire.
  28. ↑ "Clinical Trial of Centralized Lung Evaluation". Lung Bioengineering. Retrieved March 19, 2023.
  29. ↑ "United Therapeutics Corporation Form 10-Q". U.S. Securities and Exchange Commission. Retrieved March 14, 2023.
  30. ↑ Sorvino, Chloe (June 20, 2018). "How CEO Martine Rothblatt Turns Moonshots Into Earthshots". Forbes. Retrieved September 16, 2020.
  31. ↑ "Progress in Xenotransplantation Opens Door to New Supply of Critically Needed Organs". NYU Langone Health. Retrieved March 19, 2023.
  32. ↑ "The 10-gene pig and other medical science advances". UAB News. Retrieved March 15, 2023.
  33. ↑ "Quebec company behind world's first delivery of lungs by drone". October 12, 2021 Global News.
  34. ↑ "How lungs delivered by drone saved an Ontario man's life". CBC October 13, 2021.
  35. ↑ "Here's how scientists pulled off the first pig-to-human heart transplant". www.science.org. Retrieved 2022-08-20.
  36. ↑ What's the future of organ transplantation? - CNN Video, 10 June 2022, retrieved 2022-08-20
  37. ↑ "United Therapeutics Provides an Update on Its Organ Printing Programs". June 6, 2022 Yahoo Finance.
  38. ↑ United Therapeutics Corp. "Locations." Accessed October 3, 2020.
  39. ↑ "United Therapeutics Corporation: Company Profile". Dun&Bradstreet. Retrieved September 23, 2020.
  40. ↑ "United Therapeutics Corporation Form 10-K". U.S. Securities and Exchange Commission. February 21, 2024. Retrieved June 1, 2024.
  41. ↑ "NASDAQ Quote United Therapeutics Corporation (UTHE)". NASDAQ. June 1, 2024. Retrieved June 1, 2024.
  42. ↑ Silverman, Ed (December 1, 2016). "Some drug makers are better corporate citizens than others". STAT News. Retrieved March 15, 2021.
  43. ↑ "Fortune Best Workplaces in Health Care & Biopharma™ 2021". Fortune. Retrieved March 17, 2021.
  44. ↑ "Top Workplaces 2020". The Washington Post. Retrieved March 15, 2021.
  45. ↑ "Fortune Best Small & Medium Workplace 2020". Fortune. Retrieved March 15, 2021.
  46. ↑ "Fortune Best Workplaces for Millennial 2020". Fortune. Retrieved March 15, 2021.
  47. ↑ "Women in Technology 2019 Leadership Award Winners". Women in Technology. Retrieved March 9, 2021.
  48. ↑ "America's Most Responsible Companies 2022". Newsweek. Retrieved March 15, 2023.
  49. ↑ "America's Most Responsible Companies 2023". Newsweek. Retrieved March 15, 2023.
  50. ↑ United Therapeutics Corp. Accessed March 15, 2023
  51. ↑ "Letter to Shareholders". U.S. Securities and Exchange Commission. Retrieved March 12, 2023.
  52. ↑ "Letter to Shareholders". U.S. Securities and Exchange Commission. Retrieved March 18, 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.